Easy Street Investing

Latest Articles

Four investment gifts to consider buying

by Nilus Mattive |

It’s not even Thanksgiving yet, but I’ve already been getting hit with "Black Friday" shopping deals for at least two weeks now and I imagine you are, too.

Obviously, I have nothing against deep discounts on electronics or bargain-priced toys. But I also try to focus on gifts that provide longer-term value and meaning whenever possible.

So as the big period of holiday buying gets into full swing, let me give you a few investment-themed gifts to consider giving to someone in your life …

Gift Idea #1 An I-Bond

As I’ve explained plenty of times …

[Read Post »]

Little Unknown Dividend Stocks Part II

by Frank Curzio |

Earlier this month, I shared two of my favorite dividend stocks with you.

These companies have strong brands. They also have competitive moats, stable cash flows and over a 30-year history of dividend growth.

Large-cap companies like McDonald’s (MCD), Coke (KO), Wal-Mart (WMT) and ExxonMobil (XOM) fit this profile. These companies have market caps in excess of $100 billion.

However, the two companies I highlighted were Diebold (DBD) and Bemis (BMS). They have market caps of less than $5 billion. And these are two of the world’s best dividend-paying stocks.

Diebold …

[Read Post »]

Your Social Security and Retirement Questions

by Nilus Mattive |

Over the last few weeks I’ve talked a lot about the latest changes to the Social Security system as well as other retirement matters like the introduction of President Obama’s new "myRA" accounts.

In response, I’ve received plenty of questions and concerns from readers. So, I want to take a little time to address some of them today.

Let’s start with a bunch on Social Security claiming strategies…

Margaaret wrote in the following:

"My husband is 67 and still works and I will be 65 this month and also still work full-time. We both have had …

[Read Post »]

Leading the Battle Against Cancer…

by Frank Curzio |

For the first time ever, we are winning the battle against cancer. More people are living for years — instead of a few months — after being diagnosed with some of the deadliest forms of cancer. This includes melanoma, lung and pancreatic cancer. The breakthrough treatment that’s helping patients live longer is called immunotherapy. And healthcare giant Bristol-Myers Squibb (BMY) is the undisputed leader in the “Immuno-Oncology” industry. I recommended buying Bristol-Myers about a year ago. Since my call, the stock is up 12%. That’s much better than the overall market — which is trading roughly … [Read Post »]